ADMA Biologics will be a member of the Plasma Protein Therapeutics Association as a North America member effective January 1, 2020.
ADMA Biologics (NASDAQ:ADMA) has announced it has been accepted to the Plasma Protein Therapeutics Association (PPTA) effective January 1, 2020.
As quoted in the press release:
Adam Grossman, President and CEO of ADMA, will join the PPTA North America Board of Directors.
“I am honored that ADMA has been accepted to the PPTA and to be joining PPTA’s North America Board of Directors. I look forward to serving alongside some of the nation’s most prestigious leaders in the field of immunoglobulins and plasma proteins,” stated Mr. Grossman. “Given ADMA’s fractionation plant turnaround and my industry experience, we bring a deep understanding of the many unique challenges our industry currently faces and I believe we can make important contributions with the ultimate goal of efficiently bringing plasma-derived products to the patients who need them.”
“Adam brings more than two decades of leadership experience in the field of plasma proteins to PPTA, and we’re thrilled to welcome him to the team,” said Amy Efantis, PPTA’s President and CEO. “His strategic insight and operational expertise in the North American market will be invaluable as we pursue our mission to advance the plasma protein therapeutics industry to meet the needs of a global population depending on the critical, life-saving medicines produced by PPTA members.”